OVAX is AVAX’s post-surgical autologous cell vaccine for Stage 3 & 4 ovarian cancer. A Phase 1/2 clinical trial for OVAX® has completed enrollment of patients and patient data is being collected for analysis. A second multi-center controlled Phase 2 study is planned. OVAX has received US FDA Orphan Drug Status which allows for the fast-track approval process.